| Literature DB >> 21417280 |
J Martin Herold1, Tim J Wigle, Jacqueline L Norris, Robert Lam, Victoria K Korboukh, Cen Gao, Lindsey A Ingerman, Dmitri B Kireev, Guillermo Senisterra, Masoud Vedadi, Ashutosh Tripathy, Peter J Brown, Cheryl H Arrowsmith, Jian Jin, William P Janzen, Stephen V Frye.
Abstract
Proteins which bind methylated lysines ("readers" of the histone code) are important components in the epigenetic regulation of gene expression and can also modulate other proteins that contain methyl-lysine such as p53 and Rb. Recognition of methyl-lysine marks by MBT domains leads to compaction of chromatin and a repressed transcriptional state. Antagonists of MBT domains would serve as probes to interrogate the functional role of these proteins and initiate the chemical biology of methyl-lysine readers as a target class. Small-molecule MBT antagonists were designed based on the structure of histone peptide-MBT complexes and their interaction with MBT domains determined using a chemiluminescent assay and ITC. The ligands discovered antagonize native histone peptide binding, exhibiting 5-fold stronger binding affinity to L3MBTL1 than its preferred histone peptide. The first cocrystal structure of a small molecule bound to L3MBTL1 was determined and provides new insights into binding requirements for further ligand design.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21417280 PMCID: PMC3109722 DOI: 10.1021/jm200045v
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446